论文部分内容阅读
目的比较脱氧核苷酸注射液联合化疗与单纯化疗治疗晚期胃癌的临床疗效及不良反应。方法 68例晚期胃癌患者采用随机数字表法分为治疗组38例和对照组30例。治疗组采用脱氧核苷酸注射液联合化疗,对照组给予单独化疗。随访21 d评估患者的骨髓抑制、体重改变及免疫功能。结果治疗组7 d后WBC计数为(3.9±1.3)×109/L,血小板计数为(65.2±23.7)×109/L,WBC恢复正常人数占63.2%,III度+IV度骨髓抑制发生率为10.5%;对照组分别为(3.0±1.2)×109/L、(48.8±21.4)×109/L、33.3%、40.0%,两组比较差异具有统计学意义(P<0.05)。随访14 d,CD3+(62.3±18.7 VS 55.4±16.8),CD4+(39.1±14.2VS 38.3±5.0),NK细胞(33.5±12.6 VS 24.4±11.2)水平治疗组高于对照组,两组比较差异具有统计学意义(P<0.05)。另外两组治疗21 d后,治疗组肌肉不良事件发生率、肝损伤事件发生率、医院感染发生率、体重增加量、生活质量(KPS)评分提高≥10分分别为10.5%、5.3%、5.3%、(1.9±0.5)kg、65.8%;对照组则分别为50.0%、20.0%、33.3%、(-0.8±0.2)kg、40.0%,两组比较差异具有统计学意义(P<0.05)。结论脱氧核苷酸注射液减轻晚期胃癌化疗后的骨髓抑制,激活免疫功能,提高胃癌患者的体重,改善生存质量。
Objective To compare the clinical efficacy and side effects of deoxynucleotide injection with chemotherapy and chemotherapy alone in the treatment of advanced gastric cancer. Methods Sixty-eight patients with advanced gastric cancer were divided into treatment group (n = 38) and control group (n = 30) by random number table. The treatment group with deoxynucleotide injection combined with chemotherapy, the control group given chemotherapy alone. Patients were followed up for 21 days to assess bone marrow suppression, weight changes and immune function. Results The WBC count was (3.9 ± 1.3) × 109 / L and the platelet count was (65.2 ± 23.7) × 109 / L in 7 days after treatment in the treatment group, 63.2% in the normal WBC group, and the incidence of myelosuppression in grade III and IV was 10.5% in the control group and (3.0 ± 1.2) × 109 / L in the control group (48.8 ± 21.4) × 109 / L, 33.3% and 40.0% in the control group respectively. There was significant difference between the two groups (P <0.05). After 14 days of follow-up, the levels of CD3 + (62.3 ± 18.7 VS 55.4 ± 16.8), CD4 + (39.1 ± 14.2 VS 38.3 ± 5.0) and NK cells (33.5 ± 12.6 VS 24.4 ± 11.2) were higher in the treatment group than in the control group Statistical significance (P <0.05). In the other two groups, the incidence of muscular adverse events, hepatic injury, nosocomial infections, weight gain and quality of life (KPS) score increased by 10% were 10.5%, 5.3%, 5.3 %, (1.9 ± 0.5) kg and 65.8% in the control group and 50.0%, 20.0% and 33.3% in the control group (-0.8 ± 0.2) and 40.0% in the control group . Conclusion Deoxynucleotide injection can reduce the myelosuppression, activate the immune function, improve the body weight and improve the quality of life in patients with advanced gastric cancer after chemotherapy.